AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 82 min read$HSIC

HENRY SCHEIN INC (HSIC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Henry Schein Announces Chief Financial Officer Leadership Transition • Emmanuel Caprais, former Senior Vice President and CFO of ITT, Inc., to become Henry Schein’s CFO effective November 4, 2026. Mr. Caprais will join the Company in an advisory capacity beginning Oc

Original reporting
SEC EDGAR 8-K
Published Oct 8, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$HSIC
Neutral
high confidence
Mentioned
$HSIC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HSICNeutralLow
01

Why it matters

The appointment of a CFO with extensive industrial experience may be interpreted as a move to strengthen financial strategy and support margin expansion initiatives.

02

Market read

Executive turnover is a standard corporate action; while not a major catalyst, it provides fresh information for investors assessing governance and strategic execution.

03

What to watch

Potential hidden cost synergies from Caprais' industrial background that could benefit supply‑chain efficiency.

Relevance 6/10Novelty 6/10Timing: today

Background

Henry Schein (HSIC) is a Fortune‑500 provider of healthcare products and services. The 8‑K filing details a senior leadership transition in the finance function.

Company-level read

Ticker impact

$HSICNeutralHigh confidence
Context

SEC Form 8‑K announces new CFO Emmanuel Caprais effective Nov 4 2026, replacing long‑time CFO Ronald South.

Expected impact

likely modest upside as investors price in fresh financial leadership; no immediate pressure expected.

Evidence & confidence

The filing is the first public disclosure of the CFO change; such executive transitions typically have limited but measurable impact on stock perception.

Market effects

Sector

May signal continued focus on margin expansion for the healthcare distribution sector.

Regional

Limited to U.S. investors; no broader regional effect.

Global

Minimal; primarily a company‑specific governance update.

Counterpoint

What could challenge this read

The CFO change could be a distraction; execution risk remains if transition is not smooth.

Key entities

  • person
    Emmanuel Caprais

    Incoming Senior Vice President and Chief Financial Officer of Henry Schein.

  • person
    Ronald N. South

    Outgoing CFO transitioning to senior advisor role.

Read at source← All news

Related articles

OCT 8
$HSICMed

Why is Henry Schein stock sliding today?

Henry Schein's stock fell 2.5% in pre-market trading after announcing a CFO change. Emmanuel Caprais will replace Ronald N. South, who has served for 18 years, effective November 4, 2026. The company's next earnings report is scheduled for November 3, 2026. Bank of America maintained a Buy rating and $110 price target. The stock is down 6.9% over the past month, trading at $81.56 in pre-market.

investing.com2 min
SEP 15
$HSICMed

HSIC: Growth acceleration, operational rigor, and disciplined capital allocation drive strong performance

Henry Schein, Inc. [HSIC] outlined plans to accelerate growth, simplify operations, and improve operating income by $200 million, targeting double-digit EPS growth. The company highlighted strong performance in dental and medical segments, focusing on consumables, private label, and technology. Leadership emphasized disciplined M&A and share buybacks for capital allocation.

tradingview.com1 min
AUG 19
$HSICMed

Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?

Henry Schein, Inc. (HSIC) reported broad-based growth in Q2, with sales increases across distribution, specialty products, and technology. Management raised its 2026 sales and earnings guidance. HSIC trades at a discount to market benchmarks but faces risks from leverage and execution challenges. The company aims for $200M in operating income improvement by 2026, with savings initiatives underway.

tradingview.com3 min
AUG 11
$HSICMedAI 8/10

Henry Schein (HSIC) Q2 2026 Earnings Call Transcript

Henry Schein (HSIC) reported Q2 2026 net sales of $3.5 billion, up 6.7%, and non-GAAP diluted EPS of $1.27. GAAP diluted EPS was $0.82. The company raised 2026 guidance, including non-GAAP EPS to $5.29 to $5.39 and sales growth to 4.5% to 5.5%, and approved $200 million in share repurchases.

fool.com6 min